Usher 1F Collaborative Inc

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2013

Legal Domicile

Principal Officer

Melissa Chaikof

Phone

3392212743

Tax Period

2025-01-01 to 2025-12-31

Usher 1F Collaborative Inc, founded in 2013, is a small nonprofit in the Medical Research sector that reported $744K in total revenue in fiscal year 2025. Revenue decreased 12% compared to the prior year. Expenses of $885K exceeded revenue, resulting in a 19% operating deficit.

Mission

To fund medical research to find an effective treatment to save or restore the vision of those affected with Usher Syndrome Type 1F.

Program Service Accomplishments

Program 1

Expenses: $712,836

2025 Grants to Research Labs: Harvard Medical School, David Corey Lab: $320,000 Development of gene therapies for Usher 1F University of Oregon Institute of Neuroscience, Monte Westerfield Lab...

2025 Grants to Research Labs: Harvard Medical School, David Corey Lab: $320,000 Development of gene therapies for Usher 1F University of Oregon Institute of Neuroscience, Monte Westerfield Lab: $80,000 Testing existing drugs for repurposing for Usher 1F 2025 Grant for year 4 of RUSH1F, 4-year natural history study in partnership with Foundation Fighting Blindness: $200,000. 2026 is year 4 of 4. This study will provide critical data for a future clinical trial. $5000 awarded to Usher Syndroom, Netherlands, for support/sponsorship of international Usher syndrome scientific research conference Total payment to Unravel Biosciences to identify drugs for repurposing for Usher 1F: $45,610 with an additional $45,610 due early 2026 at conclusion of study. Total grants awarded in 2025: $350,610 Key Research advances realized in 2025: Harvard conducting further preclinical testing of mini-gene Harvard team published the following paper in peer-reviewed journal: Mini-Pcdh15b Gene Therapy Rescues Visual Deficits in a Zebrafish Model of Usher Syndrome Type 1F https://www.biorxiv.org/content/10.1101/2025.11.05.686814v1 2 more papers in progress from Harvard lab for publication in 2026 Corey lab is now testing gene therapy from The Salk Institute, Samuel Pfaff lab, and early results are exciting. Hired a consultant to take our mini-gene through the next steps to apply for a clinical trial. Agreement in progress. Will include with 2026 audit since its not yet signed.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $463,492

Program Service Revenue $0

Investment Income $15,727

Other Revenue $264,353

TOTAL REVENUE $743,572

Expense Breakdown

Grants Paid $696,990

Salaries & Benefits $88,971

Fundraising Expenses $135,617

Program Expenses $712,836

Other Expenses $99,524

TOTAL EXPENSES $885,485

Year-over-Year Comparison

	2025	2024	Change
Revenue	$743,572	$845,716	-0.1%
Expenses	$885,485	$871,099	+0.0%
Net Income	$-141,913	$-25,383	+4.6%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Melissa Chaikof	Chair and Trustee	40.00	Officer Director	$0	$0	$0
Elliot Chaikof	Vice Chair and Trustee	2.00	Officer Director	$0	$0	$0
Frank Gentile	Treasurer and Trustee	2.00	Officer Director	$0	$0	$0
Jared Root	Secretary and Trustee	4.00	Officer Director	$0	$0	$0
Joshua Cohen	Trustee	2.00	Director	$0	$0	$0
Rachel Root	Trustee	2.00	Director	$0	$0	$0
Julian Seewald	Trustee	2.00	Director	$0	$0	$0
Sari L Springer	Trustee	2.00	Director	$0	$0	$0
Heather Rosenstein	Trustee	2.00	Director	$0	$0	$0
Eric Halper	Trustee	2.00	Director	$0	$0	$0
Margi Levitt	Trustee	2.00	Director	$0	$0	$0
Dorie Shapiro	Trustee	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$743,572	$885,485	$691,312	$-141,913
2024	$845,716	$871,099	$781,549	$-25,383
2023	$446,533	$646,264	$810,900	$-199,731
2022	$1,082,978	$932,832	$1,300,335	$150,146
2021	$597,802	$840,065	$1,173,759	$-242,263
2020	$1,233,929	$482,557	$1,398,235	$751,372
2019	$783,556	$435,650	$646,863	$347,906
2018	$409,468	$465,981	$298,956	$-56,513